{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:00:12Z","timestamp":1791241212977,"version":"4.1.0"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aspartic proteases plasmepsin IX\/X are important antimalarial drug targets due to their specificity to the malaria parasite and their vital role as mediators of disease progression. Focusing on parasite-specific targets where no human homologue exists reduces the possibility of on-target drug toxicity. However, there is a risk of toxicity driven by inadequate selectivity for plasmepsins IX\/X in Plasmodium over related mammalian aspartic proteases. Of these, CatD\/E may be of most toxicological relevance as CatD is a ubiquitous lysosomal enzyme present in most cell types and CatE is found in the gut and in erythrocytes, the clinically significant site of malarial infection. Based on mammalian aspartic protease physiology and adverse drug reactions (ADRs) to FDA-approved human immunodeficiency virus (HIV) aspartic protease inhibitors, we predicted several potential toxicities including \u03b2-cell and congenital abnormalities, hypotension, hypopigmentation, hyperlipidaemia, increased infection risk and respiratory, renal, gastrointestinal, dermatological, and other epithelial tissue toxicities. These ADRs to the HIV treatments are likely to be a result of host aspartic protease inhibition due a lack of specificity for the HIV protease; plasmepsins are much more closely related to human CatD than to HIV proteinase. Plasmepsin IX\/X inhibition presents an opportunity to specifically target Plasmodium as an effective antimalarial treatment, providing adequate selectivity can be obtained. Potential plasmepsin IX\/X inhibitors should be assayed for inhibitory activity against the main human aspartic proteases and particularly CatD\/E. An investigative rodent study conducted early in drug discovery would serve as an initial risk assessment of the potential hazards identified.<\/jats:p>","DOI":"10.1093\/toxres\/tfaa106","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T20:49:52Z","timestamp":1607633392000},"page":"203-213","source":"Crossref","is-referenced-by-count":15,"title":["A target safety assessment of the potential toxicological risks of targeting plasmepsin IX\/X for the treatment of malaria"],"prefix":"10.1093","volume":"10","author":[{"given":"Jane","family":"Barber","sequence":"first","affiliation":[{"name":"ApconiX, Alderley Park, Alderley Edge, SK10 4TG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phumzile","family":"Sikakana","sequence":"additional","affiliation":[{"name":"ApconiX, Alderley Park, Alderley Edge, SK10 4TG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Sadler","sequence":"additional","affiliation":[{"name":"ApconiX, Alderley Park, Alderley Edge, SK10 4TG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Baud","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, 20 Route de Pr\u00e9-Bois, Geneva 1215, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[{"name":"UCB Biopharma SRL, Building R9, Chemin du Foriest, 1420 Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Roberts","sequence":"additional","affiliation":[{"name":"ApconiX, Alderley Park, Alderley Edge, SK10 4TG, UK"},{"name":"Biosciences, University of Birmingham, Edgbaston, B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2021041414032499800_ref1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"2021041414032499800_ref2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2021041414032499800_ref3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2021041414032499800_ref4","doi-asserted-by":"crossref","DOI":"10.30875\/7e6f8c91-en","volume-title":"World Malaria Report 2019","author":"World Malaria Report 2019","year":"2019"},{"key":"2021041414032499800_ref5","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(18)30324-6","article-title":"Malaria","volume":"391","author":"Ashley","year":"2018","journal-title":"Lancet"},{"key":"2021041414032499800_ref6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1086\/322858","article-title":"Chloroquine-resistant malaria","volume":"184","author":"Wellems","year":"2001","journal-title":"J Infect Dis"},{"key":"2021041414032499800_ref7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrmicro.2017.161","article-title":"Drug resistance in Plasmodium","volume":"16","author":"Haldar","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"2021041414032499800_ref8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","article-title":"Evolution and expansion of multidrug-resistant malaria in Southeast Asia: a genomic epidemiology study","volume":"19","author":"Hamilton","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021041414032499800_ref9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","article-title":"Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia","volume":"211","author":"Takala-Harrison","year":"2015","journal-title":"J Infect Dis"},{"key":"2021041414032499800_ref10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.chom.2020.02.005","article-title":"Dual Plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle","volume":"27","author":"Favuzza","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2021041414032499800_ref11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1126\/science.aan1478","article-title":"Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion","volume":"358","author":"Nasamu","year":"2017","journal-title":"Science (80- )"},{"key":"2021041414032499800_ref12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1021\/acsinfecdis.8b00197","article-title":"Fast-acting small molecules targeting malarial aspartyl proteases, Plasmepsins, inhibit malaria infection at multiple life stages","volume":"5","author":"Singh","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2021041414032499800_ref13","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1074\/jbc.REV120.009309","article-title":"Malaria parasite plasmepsins: more than just plain old degradative pepsins","volume":"295","author":"Nasamu","year":"2020","journal-title":"J Biol Chem"},{"key":"2021041414032499800_ref14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S1471-4922(01)02037-2","article-title":"Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets","volume":"17","author":"Coombs","year":"2001","journal-title":"Trends Parasitol"},{"key":"2021041414032499800_ref15","doi-asserted-by":"publisher","first-page":"7876","DOI":"10.1002\/jcb.28062","article-title":"A dual target of Plasmepsin IX and X: unveiling the atomistic superiority of a core chemical scaffold in malaria therapy","volume":"120","author":"Munsamy","year":"2019","journal-title":"J Cell Biochem"},{"key":"2021041414032499800_ref16","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/j.1742-4658.2008.06325.x","article-title":"The catalytic significance of the proposed active site residues in Plasmodium falciparum histoaspartic protease","volume":"275","author":"Parr","year":"2008","journal-title":"FEBS J"},{"key":"2021041414032499800_ref17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1073\/pnas.022630099","article-title":"Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine","volume":"99","author":"Banerjee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021041414032499800_ref18","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1128\/AAC.00882-09","article-title":"Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors","volume":"53","author":"Moura","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041414032499800_ref19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/713609213","article-title":"Aspartic peptidase inhibitors: implications in drug development","volume":"38","author":"Dash","year":"2003","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2021041414032499800_ref20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2174\/138920211797248565","article-title":"Proteases in malaria parasites - a Phylogenomic perspective","volume":"12","author":"Cai","year":"2011","journal-title":"Curr Genomics"},{"key":"2021041414032499800_ref21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1083\/jcb.201206112","article-title":"The cellular and molecular basis for malaria parasite invasion of the human red blood cell","volume":"198","author":"Cowman","year":"2012","journal-title":"J Cell Biol"},{"key":"2021041414032499800_ref22","doi-asserted-by":"publisher","first-page":"e1006453","DOI":"10.1371\/journal.ppat.1006453","article-title":"The Plasmodium falciparum pseudoprotease SERA5 regulates the kinetics and efficiency of malaria parasite egress from host erythrocytes. Billker O, ed","volume":"13","author":"Collins","year":"2017","journal-title":"PLoS Pathog"},{"key":"2021041414032499800_ref23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41564-018-0111-0","article-title":"A protease cascade regulates release of the human malaria parasite Plasmodium falciparum from host red blood cells","volume":"3","author":"Thomas","year":"2018","journal-title":"Nat Microbiol"},{"key":"2021041414032499800_ref24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.pt.2015.12.007","article-title":"Overlaying molecular and temporal aspects of malaria parasite invasion","volume":"32","author":"Weiss","year":"2016","journal-title":"Trends Parasitol"},{"key":"2021041414032499800_ref25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1126\/science.aaf8675","article-title":"A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress","volume":"358","author":"Pino","year":"2017","journal-title":"Science (80-)"},{"key":"2021041414032499800_ref26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s10930-019-09871-2","article-title":"Unveiling a new era in malaria therapeutics: a tailored molecular approach towards the Design of Plasmepsin IX inhibitors","volume":"38","author":"Munsamy","year":"2019","journal-title":"Protein J"},{"key":"2021041414032499800_ref27","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2165\/00003495-200767120-00008","article-title":"Aliskiren: a review of its use in the management of hypertension","volume":"67","author":"Frampton","year":"2007","journal-title":"Drugs"},{"key":"2021041414032499800_ref28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.lfs.2019.01.015","article-title":"Leishmanicidal therapy targeted to parasite proteases","volume":"219","author":"Machado","year":"2019","journal-title":"Life Sci"},{"key":"2021041414032499800_ref29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40425-019-0498-z","article-title":"Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies","volume":"7","author":"Ashraf","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2021041414032499800_ref30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","article-title":"Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease","volume":"28","author":"Imbimbo","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"2021041414032499800_ref31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10930-017-9735-9","article-title":"Sequence, structural analysis and metrics to define the unique dynamic features of the flap regions among aspartic proteases","volume":"36","author":"McGillewie","year":"2017","journal-title":"Protein J"},{"key":"2021041414032499800_ref32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/jmr.1091","article-title":"Looking at the proteases from a simple perspective","volume":"24","author":"Castro","year":"2011","journal-title":"J Mol Recognit"},{"key":"2021041414032499800_ref33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/271618a0","article-title":"Structural evidence for gene duplication in the evolution of the acid proteases","volume":"271","author":"Tang","year":"1978","journal-title":"Nature"},{"key":"2021041414032499800_ref34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s0163-7258(00)00037-1","article-title":"Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance","volume":"86","author":"Swanstrom","year":"2000","journal-title":"Pharmacol Ther"},{"key":"2021041414032499800_ref35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ejmech.2018.11.068","article-title":"Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D","volume":"163","author":"Zogota","year":"2019","journal-title":"Eur J Med Chem"},{"key":"2021041414032499800_ref36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4939-7172-5_12","volume-title":"Methods in Molecular Biology","author":"Brennan","year":"2017"},{"key":"2021041414032499800_ref37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/toxsci\/kfy270","article-title":"Today\u2019s challenges to De-risk and predict drug safety in human \u201cmind-the-gap\u201d","volume":"167","author":"Weaver","year":"2019","journal-title":"Toxicol Sci"},{"key":"2021041414032499800_ref38","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.drudis.2018.05.028","article-title":"Understanding drug targets: no such thing as bad news","volume":"23","author":"Roberts","year":"2018","journal-title":"Drug Discov Today"},{"key":"2021041414032499800_ref39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1042\/bj1170601","article-title":"Purification of isoenzymes from human and chicken liver","volume":"117","author":"Barrett","year":"1970","journal-title":"Biochem J"},{"key":"2021041414032499800_ref40","doi-asserted-by":"crossref","first-page":"13403","DOI":"10.1016\/S0021-9258(18)80010-2","article-title":"Cleavage of parathyroid hormone in macrophage endosomes illustrates a novel pathway for intracellular processing of proteins","volume":"264","author":"Diment","year":"1989","journal-title":"J Biol Chem"},{"key":"2021041414032499800_ref41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","article-title":"Cathepsin D-many functions of one aspartic protease","volume":"68","author":"Benes","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021041414032499800_ref42","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1074\/jbc.M504670200","article-title":"Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L","volume":"281","author":"Baechle","year":"2006","journal-title":"J Biol Chem"},{"key":"2021041414032499800_ref43","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/01.ATV.0000077207.49221.06","article-title":"Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions","volume":"23","author":"Hakala","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021041414032499800_ref44","first-page":"79","article-title":"Biological and diagnostic role of cathepsin D","volume":"42","author":"Ba\u0144kowska","year":"1997","journal-title":"Rocz Akad Med Bialymst"},{"key":"2021041414032499800_ref45","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1242\/jcs.01396","article-title":"Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions","volume":"117","author":"Lkhider","year":"2004","journal-title":"J Cell Sci"},{"key":"2021041414032499800_ref46","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1002\/j.1460-2075.1995.tb00029.x","article-title":"Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells","volume":"14","author":"Saftig","year":"1995","journal-title":"EMBO J"},{"key":"2021041414032499800_ref47","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/brain\/awl107","article-title":"Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis","volume":"129","author":"Siintola","year":"2006","journal-title":"Brain"},{"key":"2021041414032499800_ref48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/brain\/awl132","article-title":"Another disorder finds its gene","volume":"129","author":"Ramirez-Montealegre","year":"2006","journal-title":"Brain"},{"key":"2021041414032499800_ref49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms13042","article-title":"Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of \u03b2-secretase inhibitors","volume":"7","author":"Zuhl","year":"2016","journal-title":"Nat Commun"},{"key":"2021041414032499800_ref50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbrc.2007.12.163","article-title":"A mini review","volume":"367","author":"Zaidi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"2021041414032499800_ref51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/jb\/mvj132","article-title":"Cathepsin E-deficient mice show increased susceptibility to bacterial infection associated with the decreased expression of multiple cell surface toll-like receptors","volume":"140","author":"Tsukuba","year":"2006","journal-title":"J Biochem"},{"key":"2021041414032499800_ref52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/JB","article-title":"Association of Cathepsin E Deficiency with development of atopic dermatitis","volume":"145","author":"Tsukuba","year":"2003","journal-title":"J Biochem"},{"key":"2021041414032499800_ref53","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1074\/jbc.M604143200","article-title":"Cathepsin E deficiency induces a novel form of lysosomal storage disorder showing the accumulation of lysosomal membrane sialoglycoproteins and the elevation of lysosomal pH in macrophages","volume":"282","author":"Yanagawa","year":"2007","journal-title":"J Biol Chem"},{"key":"2021041414032499800_ref54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/CS20100432","article-title":"Renin, (pro)renin and receptor: an update","volume":"120","author":"Nguyen","year":"2011","journal-title":"Clin Sci"},{"key":"2021041414032499800_ref55","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1042\/CS20180121","article-title":"Intratubular and intracellular renin-angiotensin system in the kidney: a unifying perspective in blood pressure control","volume":"132","author":"Li","year":"2018","journal-title":"Clin Sci"},{"key":"2021041414032499800_ref56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/14756368709020115","article-title":"Inhibitors of renin as potential therapeutic agents","volume":"1","author":"Wood","year":"1987","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2021041414032499800_ref57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.foodchem.2018.06.042","article-title":"Revisiting the enzymatic kinetics of pepsin using isothermal titration calorimetry","volume":"268","author":"Luo","year":"2018","journal-title":"Food Chem"},{"key":"2021041414032499800_ref58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/PAP.0b013e31823e472e","article-title":"Napsin A expression in lung and kidney neoplasia: a review and update","volume":"19","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Adv Anat Pathol"},{"key":"2021041414032499800_ref59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0014-5793(99)01493-3","article-title":"Napsin a, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas","volume":"462","author":"Chuman","year":"1999","journal-title":"FEBS Lett"},{"key":"2021041414032499800_ref60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/labinvest.3700718","article-title":"The aspartic protease napsin a suppresses tumor growth independent of its catalytic activity","volume":"88","author":"Ueno","year":"2008","journal-title":"Lab Invest"},{"key":"2021041414032499800_ref61","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1679\/aohc.65.359","article-title":"Immunohistochemical localization of napsin and its potential role in protein catabolism in renal proximal tubules","volume":"65","author":"Mori","year":"2002","journal-title":"Arch Histol Cytol"},{"key":"2021041414032499800_ref62","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev.physiol.63.1.555","article-title":"Function of surfactant proteins B and C","volume":"63","author":"Weaver","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"2021041414032499800_ref63","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/ki.2013.284","article-title":"The role of the kidney in protein metabolism: the capacity of tubular lysosomal proteolysis in nephrotic syndrome","volume":"84","author":"Tojo","year":"2013","journal-title":"Kidney Int"},{"key":"2021041414032499800_ref64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jnc.12715","article-title":"Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects","volume":"130","author":"Vassar","year":"2014","journal-title":"J Neurochem"},{"key":"2021041414032499800_ref65","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1126\/science.1132341","article-title":"Control of peripheral nerve myelination by the \u03b2-secretase BACE1","volume":"314","author":"Willem","year":"2006","journal-title":"Science (80-)"},{"key":"2021041414032499800_ref66","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1074\/jbc.M109266200","article-title":"Substrate and inhibitor profile of BACE (\u03b2-secretase) and comparison with other mammalian aspartic proteases","volume":"277","author":"Gr\u00fcninger-Leitch","year":"2002","journal-title":"J Biol Chem"},{"key":"2021041414032499800_ref67","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1038\/emboj.2013.146","article-title":"Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles","volume":"32","author":"Cheret","year":"2013","journal-title":"EMBO J"},{"key":"2021041414032499800_ref68","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1128\/AAC.00840-06","article-title":"Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro","volume":"51","author":"Skinner-Adams","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041414032499800_ref69","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.2174\/1568026619666181130133548","article-title":"Antimalarials: review of Plasmepsins as drug targets and HIV protease inhibitors interactions","volume":"18","author":"Miller","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"2021041414032499800_ref70","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1128\/AAC.50.2.639-648.2006","article-title":"Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria","volume":"50","author":"Andrews","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041414032499800_ref71","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1086\/425584","article-title":"Antiretrovirals as antimalarial agents","volume":"190","author":"Skinner-Adams","year":"2004","journal-title":"J Infect Dis"},{"key":"2021041414032499800_ref72","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/hiv.12733","article-title":"Adverse effects of chronic treatment with the main subclasses of highly active antiretroviral therapy: a systematic review","volume":"20","author":"Silva","year":"2019","journal-title":"HIV Med"},{"key":"2021041414032499800_ref73","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1086\/377288","article-title":"Randomized trial to evaluate Indinavir\/ritonavir versus Saquinavir\/ritonavir in human immunodeficiency virus type 1\u2013infected patients: the MaxCmin1 trial","volume":"188","author":"Dragsted","year":"2003","journal-title":"J Infect Dis"},{"key":"2021041414032499800_ref74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1293.2005.00255.x","article-title":"Indinavir\/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800\/100 mg and 400\/100 mg twice daily","volume":"6","author":"Konopnicki","year":"2005","journal-title":"HIV Med"},{"key":"2021041414032499800_ref75","doi-asserted-by":"publisher","first-page":"e0144917","DOI":"10.1371\/journal.pone.0144917","article-title":"Tipranavir\/ritonavir (500\/200 mg and 500\/100 mg) was Virologically non-inferior to Lopinavir\/ritonavir (400\/100 mg) at week 48 in treatment-Na\u00efve HIV-1-infected patients: a randomized, multinational, Multicenter trial. Landay a, ed","volume":"11","author":"Cooper","year":"2016","journal-title":"PLoS One"},{"key":"2021041414032499800_ref76","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/jac\/dku501","article-title":"Atherogenic properties of lipoproteins in HIV patients starting atazanavir\/ritonavir or darunavir\/ritonavir: a substudy of the ATADAR randomized study","volume":"70","author":"Saumoy","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021041414032499800_ref77","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1086\/432079","article-title":"Antimalarial effects of HIV proteinase inhibitors: common compounds but structurally distinct enzymes","volume":"192","author":"Wyatt","year":"2005","journal-title":"J Infect Dis"},{"key":"2021041414032499800_ref78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nsmb.2203","article-title":"New approaches for dissecting protease functions to improve probe development and drug discovery","volume":"19","author":"Deu","year":"2012","journal-title":"Nat Struct Mol Biol"}],"container-title":["Toxicology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/toxres\/article-pdf\/10\/2\/203\/37051199\/tfaa106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/toxres\/article-pdf\/10\/2\/203\/37051199\/tfaa106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T18:42:28Z","timestamp":1618598548000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxres\/article\/10\/2\/203\/6135370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":78,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/toxres\/tfaa106","relation":{},"ISSN":["2045-4538"],"issn-type":[{"value":"2045-4538","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,2,15]]}}}